Article Detail - JF Part A
MolDX: Breast Cancer Assay: Prosigna - R5 - Effective April 22, 2021
This Local Coverage Determination (LCD) has been revised under contractor numbers: 02101 (AK), 02201 (ID), 02301 (OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT), and 03601 (WY).
Medicare Coverage Database (MCD) Number: L36386
LCD Title: MolDX: Breast Cancer Assay: Prosigna®
Effective Date: April 22, 2021
Summary of Changes:
Under LCD Title: Added a registered mark to Prosigna®
Under CMS National Coverage Policy: Added regulation CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15, §80 Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests and §80.1.1 Certification Changes.
Under Bibliography: Changes were made to citations to reflect AMA citation guidelines. Prosigna® was inserted throughout the LCD where applicable. Formatting, punctuation, and typographical errors were corrected throughout the LCD. Acronyms were defined and inserted where appropriate throughout the LCD.
Visit the Active LCDs webpage to view the locally hosted Active LCD or access it via the CMS MCD.
Last Updated Wed, 21 Apr 2021 17:03:41 +0000